Squarepoint Ops LLC Jounce Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $22,787 - $70,855	35,606 New	35,606 $39,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $66,434 - $94,401	-11,054 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $20,533 - $27,840	-2,888 Reduced 20.71%	11,054 $92,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $252,115 - $436,700	-50,023 Reduced 78.2%	13,942 $104,000
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $341,442 - $553,158	51,891 Added 429.77%	63,965 $435,000
Q1 2021 May 17, 2021	SELL	$6.73 - $13.87 $497,077 - $1.02 Million	-73,860 Reduced 85.95%	12,074 $124,000
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $343,960 - $557,789	53,997 Added 169.07%	85,934 $602,000
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $146,271 - $349,710	31,937 New	31,937 $261,000
Q1 2019 May 15, 2019	SELL	$3.43 - $6.87 $262,247 - $525,259	-76,457 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.69 - $6.71 $145,120 - $361,991	53,948 Added 239.67%	76,457 $258,000
Q3 2018 Nov 14, 2018	BUY	$6.5 - $8.37 $146,308 - $188,400	22,509 New	22,509 $146,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.